Ratings SUSMED,Inc.

Equities

4263

JP3319150003

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-15 EDT			5-day change	1st Jan Change
534 ^JPY	-4.13%		-5.65%	-60.00%

2023	SUSMED,Inc.(TSE:4263) added to S&P Global BMI Index	CI
2022	Walgreens Boots Alliance, Inc. Joins Sustainable Medicines Partnership	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: IT Services & Consulting

	1st Jan change	Capi.	ESG Refinitiv
SUSMED,INC.	-60.00%	59.57M	-
ACCENTURE PLC	-12.51%	193B	A-
TATA CONSULTANCY SERVICES LTD.	+2.29%	169B	B+
IBM	+2.79%	154B	B-
AUTOMATIC DATA PROCESSING, INC.	+5.97%	100B	A-
RELX PLC	+11.32%	80.96B	A-
CROWDSTRIKE HOLDINGS, INC.	+34.78%	79.71B	C-
INFOSYS LIMITED	-7.97%	70.64B	A
SNOWFLAKE INC.	-17.26%	53.75B	C
HCL TECHNOLOGIES LIMITED	-9.09%	42.84B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes